Association of Extended Dosing Intervals or Delays in Pembrolizumab-based Regimens With Survival Outcomes in Advanced Nonesmall-cell Lung Cancer

Files

BulumulleAssociationofExtendedDosingIntervalsorDelaysinPembrolizumabbasedRegimens.pdf (884.2 KB)

Date

Authors

Bulumulle, Anushi

Macherla, Shravanti

Walker, Paul R.

Qilleri, Aleksandra

McDonald, Danielle C.

Cherry, Cynthia R.

Keywords

Extended-interval dosing, Immune-related adverse event, Patient-physician preference

URI

http://hdl.handle.net/10342/11327

DOI

10.1016/j.cllc.2020.05.028

Collections

Internal Medicine